Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Asıl Yazarlar: Xiaomin Wan (Yazar), Xiaohui Zeng (Yazar), Liubao Peng (Yazar), Ye Peng (Yazar), Qiao Liu (Yazar), Lidan Yi (Yazar), Xia Luo (Yazar), Qijian Deng (Yazar), Chongqing Tan (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...